Maine CDC Health Advisory

January 26, 2023

Evusheld No Longer Authorized for Emergency Use in the U.S.

The U.S. Food and Drug Administration (FDA) announced on January 26, 2023, that the Emergency Use Authorization (EUA) for Evusheld (tixagevimab co-packaged with cilgavimab) has been revised and based on this revision, Evusheld is not currently authorized for use in the U.S. This is because it is unlikely to be active against more than 90% of the SARS-CoV-2 variants currently circulating in the U.S. based on the latest CDC data. However, people who have used Evusheld still have options to increase their protection against the most serious consequences of COVID-19, including hospitalization and death.

Advisory (PDF)